Pfizer wraps up King Pharmaceuticals acquisition
Pfizer Inc. has closed its $3.6 billion deal to acquire branded drug maker King Pharmaceuticals Inc. Pfizer said Tuesday that it has completed the acquisition through the merger of its Parker Tennessee Corp. subsidiary into King, which is now a wholly owned subsidiary of Pfizer.